0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Abroad |

Epidemic Visceral Leishmaniasis in Southern Sudan: Treatment of Severely Debilitated Patients under Wartime Conditions and with Limited Resources

Jill Seaman, MD; Alec J. Mercer, MSc, MPhil; H. Egbert Sondorp, MD, MPH; and Barbara L. Herwaldt, MD, MPH
[+] Article and Author Information

From Medecins Sans Frontieres-Holland, Amsterdam, the Netherlands, and the Centers for Disease Control and Prevention, Atlanta, Georgia. Acknowledgments: The authors thank Marga Goris for data entry; Allen W. Hightower for statistical advice; the Medecins Sans Frontieres-Holland expatriate staff and the Sudanese staff, especially Francis Galeak, who worked in the southern Sudan program; and especially the patients and their relatives, who showed remarkable resilience, courage, and dignity, despite tremendous adversity. Requests for Reprints: Barbara L. Herwaldt, MD, MPH, Centers for Disease Control and Prevention, Division of Parasitic Diseases, Mailstop F-22, 4770 Buford Highway NE, Atlanta, GA 30341-3724. Current Author Addresses: Dr. Seaman: Medecins Sans Frontieres-Holland, Box 40643, Nairobi, Kenya.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1996;124(7):664-672. doi:10.7326/0003-4819-124-7-199604010-00007
Text Size: A A A

Objectives: 1] To determine the proportions of patients with visceral leishmaniasis who had various treatment outcomes when cared for under wartime conditions and with limited resources and 2) to identify patient characteristics associated with the outcomes.

Design: Cohort study.

Setting: Medicins sans Frontieres-Holland's treatment center in Duar, Western Upper Nile province, an area in southern Sudan that has been severely affected by Sudan's civil war and a massive epidemic of visceral leishmaniasis.

Patients: 3076 consecutive patients who had visceral leishmaniasis, were admitted to the treatment center the first year the center was operational (August 1990 to July 1991), and were treated with the pentavalent antimonial compound sodium stibogluconate.

Measurements: Patient characteristics on admission and four mutually exclusive treatment outcomes (default during first admission, death during first admission, discharge and readmission for retreatment [relapse], and discharge and no readmission for retreatment [successful treatment]).

Results: The patients had a median age of 15 years and were notably anemic (median hemoglobin level, 77 g/L) and malnourished (median body mass index of adults [more than equals 18 years of age], 15.2 kg/m2); most (91.0%) had been sick less than 5 months. Although patients could not be monitored after treatment to document cure, most (2562 [83.3%]) were successfully treated; 336 (10.9%) died during their first admission, and 79 are known to have relapsed (3.0% of those discharged alive [that is, those whose final treatment outcome was successful treatment or relapse]). In univariable analysis, young and older age (< 5 or more than equals 45 years of age), long duration of illness (≥ 5 months), markedly low hemoglobin level or body mass index, large spleen, high parasite density, and vomiting at least once during the treatment course were associated with death. In multiple logistic regression analysis of data for a subgroup of 1207 adults (those who did not default or relapse and for whom data were recorded on age, sex, duration of illness, hemoglobin level, body mass index, and spleen size), the approximate risk ratios for death were 2.2 (95% CI, 1.4 to 3.6) for those with a long duration of illness, 3.6 (CI, 2.1 to 5.9) for those 45 years of age or older, 4.6 (CI, 2.2 to 9.4) for those with a hemoglobin level less than 60 g/L, and 12.2 (CI, 3.2 to 47.2) for those with a body mass index less than 12 kg/m2.

Conclusion: Despite the severe debility of the patients and the exceptionally difficult circumstances under which they were treated, most fared remarkably well.

Figures

Grahic Jump Location
Figure 1.
Map of Sudan.

The sites (Duar and Ler) of Medicins sans Frontieres-Holland's two treatment centers for visceral leishmaniasis in Western Upper Nile province, southern Sudan, are shown. Khartoum is in northern Sudan.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)